ACIP's HBV birth-dose vaccine recommendations: a fiasco The Lancet Gastroenterology & Hepatology +++ +...

ACIP's HBV birth-dose vaccine recommendations: a fiasco The Lancet Gastroenterology & Hepatology https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00377-2/fulltext?dgcid=raven_jbs_etoc_email Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial Jess L Kaplan, MDa ∙ Prof Athos Bousvaros, MDb ∙ Prof Dan Turner, MDc ∙ Marla Dubinsky, MDd ∙ Amy Larkin, BSe ∙ Jordan Johns, PhDe ∙ et al https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00196-7/abstract?dgcid=raven_jbs_etoc_feature_langas Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials Jian Li, MDa,b,† ∙ Zhenghang Wang, MDb,† ∙ Prof Jing Huang, MDc,† ∙ Prof Yi Ba, MDd,† ∙ Baoshan Cao, MDe ∙ Prof Suxia Luo, MDf ∙ et al. https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00267-5/abstract?dgcid=raven_jbs_etoc_feature_langas Feb 2026 Volume 11Number 2p87-174, e1 https://www.thelancet.com/journals/langas/issue/vol11no2/PIIS2468-1253(25)X0013-3